Condition: Richter Transformation · Sponsor: German CLL Study Group
The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation
This description comes directly from the study's public registry record.
Barbara Eichhorst, Prof. · +4922147888220 · barbara.eichhorst@uk-koeln.de
Othman Al-Sawaf, MD · +4922147888220 · othman.al-sawaf@uk-koeln.de
Always discuss trial participation with your own doctor first.
| Allgemeines Krankenhaus der Stadt Wien | Vienna, Austria | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Charité Berlin | Berlin, State of Berlin, Germany | Not Yet Recruiting |
| Uniklinik Köln | Cologne, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus | Dresden, Germany | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Recruiting |
| Universitätsklinikum Schleswig-Holstein Campus Kiel | Kiel, Germany | Recruiting |
| H.O.T Praxis Landshut | Landshut, Germany | Recruiting |
| Brüderkrankenhaus St. Josef Paderborn | Paderborn, Germany | Recruiting |
| Universitätsmedizin Rostock | Rostock, Germany | Recruiting |
| Universitätsklinik Ulm | Ulm, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04271956